Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to scpJAK/scp Inhibitor and Dazukibart Therapy

Journal:

Arthritis & Rheumatology

Published:

2025-08-01

DOI:

10.1002/art.43145

Affiliations:

5

Authors:

14

Go to article

Institutions	Authors	Share
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	7.000000	0.50
NIH National Cancer Institute (NCI), United States of America (USA)	3.000000	0.21
Frederick National Laboratory for Cancer Research (FNLCR), United States of America (USA)	2.000000	0.14
Hospital St. Josef, Germany	1.000000	0.07
NIH Clinical Center, United States of America (USA)	1.000000	0.07

Interested in Immunology?